Literature DB >> 29040686

The World Health Organization's Response to Emerging Human Immunodeficiency Virus Drug Resistance and a Call for Global Action.

Silvia Bertagnolio1, Rachel L Beanland2, Michael R Jordan3, Meg Doherty1, Gottfried Hirnschall1.   

Abstract

The global community, including the World Health Organization (WHO), has committed to ending the AIDS epidemic and to ensuring that 90% of people living with human immunodeficiency virus (HIV) are diagnosed, 90% start treatment, and 90% achieve and maintain virological suppression. The emergence of HIV drug resistance (HIVDR) as antiretroviral treatment programs expand could preclude the 90-90-90 targets adopted by the United Nations General Assembly at the High-Level Meeting on Ending AIDS from being achieved. The Global Action Plan on HIVDR is a call for collective action grounded on normative guidance providing a standardized and robust approach to monitoring, preventing, and responding to HIVDR over the next 5 years (2017-2021). WHO is committed to supporting country, global, regional, and national partners to implement and monitor the progress of the Global Action Plan. This article outlines the key components of WHO's strategy to tackle HIVDR and the role the organization takes in leading the global response to HIVDR.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  drug resistance; human immunodeficiency virus (HIV); monitoring; prevention; response

Mesh:

Substances:

Year:  2017        PMID: 29040686      PMCID: PMC5853942          DOI: 10.1093/infdis/jix402

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.

Authors:  Marie-Laure Chaix; Loic Desquilbet; Diane Descamps; Dominique Costagliola; Christiane Deveau; Julie Galimand; Cécile Goujard; Anne Signori-Schmuck; Veronique Schneider; Catherine Tamalet; Isabelle Pellegrin; Marc Wirden; Bernard Masquelier; Francoise Brun-Vezinet; Christine Rouzioux; Laurence Meyer
Journal:  Antivir Ther       Date:  2007

2.  Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.

Authors:  Wendy P Bannister; Alessandro Cozzi-Lepri; Bonaventura Clotet; Amanda Mocroft; Jesper Kjaer; Peter Reiss; Viktor von Wyl; Adriano Lazzarin; Christine Katlama; Andrew N Phillips; Lidia Ruiz; Jens D Lundgren
Journal:  J Acquir Immune Defic Syndr       Date:  2008-07-01       Impact factor: 3.731

3.  Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.

Authors:  David C Knox; Peter L Anderson; P Richard Harrigan; Darrell H S Tan
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

4.  Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.

Authors:  Praphan Phanuphak; Sunee Sirivichayakul; Awachana Jiamsakul; Somnuek Sungkanuparph; Nagalingeswaran Kumarasamy; Man Po Lee; Thira Sirisanthana; Pacharee Kantipong; Christopher Lee; Adeeba Kamarulzaman; Mahiran Mustafa; Rossana Ditangco; Tuti Merati; Winai Ratanasuwan; Thida Singtoroj; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

5.  Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial.

Authors:  Rami Kantor; Laura Smeaton; Saran Vardhanabhuti; Sarah E Hudelson; Carol L Wallis; Srikanth Tripathy; Mariza G Morgado; Shanmugham Saravanan; Pachamuthu Balakrishnan; Marissa Reitsma; Stephen Hart; John W Mellors; Elias Halvas; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Alberto La Rosa; Umesh G Lalloo; Javier R Lama; Mohammed Rassool; Breno R Santos; Khuanchai Supparatpinyo; James Hakim; Timothy Flanigan; Nagalingeswaran Kumarasamy; Thomas B Campbell; Susan H Eshleman
Journal:  Clin Infect Dis       Date:  2015-02-13       Impact factor: 9.079

6.  Virological efficacy with first-line antiretroviral treatment in India: predictors of viral failure and evidence of viral resuppression.

Authors:  Anita Shet; Ujjwal Neogi; N Kumarasamy; Ayesha DeCosta; Suresh Shastri; Bharat Bhushan Rewari
Journal:  Trop Med Int Health       Date:  2015-07-24       Impact factor: 2.622

7.  Antiretroviral therapies in women after single-dose nevirapine exposure.

Authors:  Shahin Lockman; Michael D Hughes; James McIntyre; Yu Zheng; Tsungai Chipato; Francesca Conradie; Fred Sawe; Aida Asmelash; Mina C Hosseinipour; Lerato Mohapi; Elizabeth Stringer; Rosie Mngqibisa; Abraham Siika; Diana Atwine; James Hakim; Douglas Shaffer; Cecilia Kanyama; Kara Wools-Kaloustian; Robert A Salata; Evelyn Hogg; Beverly Alston-Smith; Ann Walawander; Eva Purcelle-Smith; Susan Eshleman; James Rooney; Sibtain Rahim; John W Mellors; Robert T Schooley; Judith S Currier
Journal:  N Engl J Med       Date:  2010-10-14       Impact factor: 91.245

8.  Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.

Authors:  T Sonia Boender; Bernice M Hoenderboom; Kim C E Sigaloff; Raph L Hamers; Maureen Wellington; Tinei Shamu; Margaret Siwale; Eman E F Labib Maksimos; Immaculate Nankya; Cissy M Kityo; Titilope A Adeyemo; Alani Sulaimon Akanmu; Kishor Mandaliya; Mariette E Botes; Pascale Ondoa; Tobias F Rinke de Wit
Journal:  Clin Infect Dis       Date:  2015-08-03       Impact factor: 9.079

9.  Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa.

Authors:  Andrew N Phillips; John Stover; Valentina Cambiano; Fumiyo Nakagawa; Michael R Jordan; Deenan Pillay; Meg Doherty; Paul Revill; Silvia Bertagnolio
Journal:  J Infect Dis       Date:  2017-05-01       Impact factor: 5.226

10.  The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.

Authors:  Nicola E Mackie; David T Dunn; David Dolling; Lucy Garvey; Linda Harrison; Esther Fearnhill; Peter Tilston; Caroline Sabin; Anna M Geretti
Journal:  AIDS       Date:  2013-09-10       Impact factor: 4.177

View more
  2 in total

1.  Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi.

Authors:  George Bello; Matthew Kagoli; Sikhona Chipeta; Andrew Auld; Joy C-W Chang; Joshua R DeVos; Evelyn Kim; Jonathan Mkungudza; Danielle Payne; Michael Eliya; Rose Nyirenda; Andreas Jahn; Taziona Mzumara; Bernard Mvula; Sufia Dadabhai; Ireen Namakhoma; Yusuf Babaye; Amalia Giron; Michael R Jordan; Silvia Bertagnolio; Gabrielle O'Malley; Nellie Wadonda-Kabondo
Journal:  Antivir Ther       Date:  2022-08       Impact factor: 1.679

2.  High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016.

Authors:  Amalia Girón-Callejas; Claudia García-Morales; Ricardo Mendizabal-Burastero; Matilde Román; Daniela Tapia-Trejo; Marissa Pérez-García; Verónica S Quiroz-Morales; Sandra I Juárez; Giovanni Ravasi; Carlos Vargas; René Gutiérrez; Luz Romero; Aleyda Solórzano; Edgar Sajquim; Sanny Northbrook; Santiago Ávila-Ríos; Gustavo Reyes-Terán
Journal:  J Int AIDS Soc       Date:  2019-12       Impact factor: 5.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.